Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PTAFR | P25105 | 2/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.32 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.32 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.32 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26596922 | 1.00 | ACHE (0.39) | ACHEPTPN1CYP3A4PTAFRMAPK3 | |
| SCHEMBL18917374 | 0.85 | ALDH1A1 (0.38) | ACHEMAPK3MAPK1ALOX5L3MBTL1 | |
| SCHEMBL18932275 | 0.85 | ALDH1A1 (0.38) | ACHEMAPK3MAPK1ALOX5L3MBTL1 | |
| SCHEMBL26660541 | 0.74 | SLC6A2 (0.36) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL17758012 | 0.74 | PTGS2 (0.42) | ACHECYP3A4MAPK1L3MBTL1PTGS2 | |
| SCHEMBL19546163 | 0.71 | HTR2A (0.40) | ACHECYP3A4L3MBTL1PTGS2TUBB4A | |
| SCHEMBL17375719 | 0.70 | ACHE (0.51) | ACHEPTPN1CYP3A4PTAFRMAPK3 | |
| SCHEMBL17371470 | 0.70 | ACHE (0.51) | ACHEPTPN1CYP3A4PTAFRMAPK3 | |
| SCHEMBL18943820 | 0.69 | L3MBTL1 (0.37) | ACHECYP3A4MAPK1ALOX5L3MBTL1 | |
| SCHEMBL18943821 | 0.69 | MAPT (0.40) | CYP3A4MAPK1L3MBTL1TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160462-B1 | LEOLIGIN DERIVATIVES AS PROLIFERATION INHIBITORS OF SMOOTH MUSCLE CELLS | UNIV WIEN TECH (AT) | 2023-11-22 | — | — | EP | disclosed |
| EP-3160462-B1 | LEOLIGIN DERIVATIVES AS PROLIFERATION INHIBITORS OF SMOOTH MUSCLE CELLS | UNIV WIEN TECH (AT) | 2023-11-22 | — | — | EP | disclosed |
| EP-4265602-A2 | LEOLIGIN DERIVATIVES AS PROLIFERATION INHIBITORS OF SMOOTH MUSCLE CELLS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265602-A2 | LEOLIGIN DERIVATIVES AS PROLIFERATION INHIBITORS OF SMOOTH MUSCLE CELLS | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2023-10-25 | — | — | EP | disclosed |
| US-20170157301-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | TECHNISCHE UNIVERSITÄET WIEN (AT) | 2017-06-08 | — | — | US | disclosed |
| US-20170157301-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | TECHNISCHE UNIVERSITÄET WIEN (AT) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157301-A1 | LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS | CCNH, MYLK, CCAR2 | ACHE 2780/4885PTPN1 4559/4885CYP3A4 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.